NEW YORK, January 5, 2017 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration and development company will present at the 9th Annual Biotech Showcase™ 2017 being held January 9-11, 2017 at the Hilton San Francisco Union Square, California. Taking place during one of the industry's largest annual healthcare investor conferences, this investor and partnering conference attracts pharmaceutical executives from around the world focused on investment and business development opportunities in the life sciences industry.
Conference Presentation Details:
Presenter: Denis Corin – CEO
Where: Hilton San Francisco Union Square, 333 O'Farrell Street, San Francisco, CA 94102
When: Tuesday, January 10, 2017
Time: 8:00 AM
Room: Room 3 – Ballroom Level
Webcast: https://event.webcasts.com/viewer/event.jsp?ei=1130761 live and replay 2hr after the event.
Conference Website: Biotech Showcase 2017
Q BioMed management will host one-on-one meetings with investors at the conference between January 9-11, 2017. To meet with us, please submit a meeting request via the PartneringOne scheduling system.
In addition we provide this update to those unable to attend.
2016 was essentially our inaugural year, being our first full calendar year pursuing innovative opportunities in the biotechnology space. It was a very busy year as the Company established itself in the space and commenced its effort to find innovative technologies and management teams with inherent, yet unrealized, value. By adding strategic resources to accelerate the development of those technologies, we hope to realize that value.
We closed 2016 with two pipeline technologies under the 'Q' umbrella; essentially bookends of the multi-asset business model we are building. One early stage, opportunity in the highly sought after glaucoma space and one FDA approved, drug for bone cancer palliation. In addition, we recently secured the funding to allow us to execute on the near term milestones to advance our business.
Over the course of the next several months we will continue performing due diligence on additional attractive assets with the goal of adding one or more to our pipeline in calendar 2017.
Review of Strontium Chloride 89 Injection (SR89):
In September 2016 we licensed an FDA approved drug that provides relief for patients suffering from debilitating bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. It has been proven to provide a long-term effect resulting in cancer pain relief and enhanced quality of life.
Revenue from sales of our non-narcotic pain palliative drug will be a major catalyst for Q BioMed and we look forward to providing additional guidance on the timing of this in the near future.
Review of Man-01 our glaucoma asset licensed from Mannin Research Inc:
The MAN-01 asset for treatment of Primary Open Angle Glaucoma (POAG), is continuing to progress in its pre-clinical lead candidate optimization of a small molecule for a topical application.
Mannin will continue with preclinical research and development activities for 2017 before progressing into IND enabling studies, expected in 2018 to be followed by first in human proof-of-concept clinical trials.
Our efforts in establishing research and development partnerships with commercial partners, as well as government organizations to provide technical and financial support for the development of MAN-01 for POAG is ongoing. To this end, Mannin is continuing strategic partnership discussions with companies and technologies that will strengthen its intellectual property portfolio in the Tie2/TEK mechanism of action market.
Thank you for your interest in Q BioMed and we hope you continue following our progress.
Happy New Year and may it bring you good health, happiness and prosperity!
About Q BioMed Inc.
Q BioMed Inc.”Q” is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need.
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy, revenue generation and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Q BioMed Inc.